ID4PHARMA, LLC

Biotech · Private

Small-molecule p62 ZZ-domain inhibitors for multiple myeloma treatment

Grants
$2.3M
4 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
1 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · SQSTM1/p62-targeted Small Molecules for Multiple Myeloma Disease$300,000
Federal grantDepartment of Health and Human Services · Phase II · SQSTM1/p62-targeted Small Molecules for Multiple Myeloma Disease$6,840
Federal grantDepartment of Health and Human Services · Phase II · SQSTM1/p62-targeted Small Molecules for Multiple Myeloma Disease$1,000,000
Federal grantDepartment of Health and Human Services · Phase II · SQSTM1/p62-targeted Small Molecules for Multiple Myeloma Disease$1,000,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2176AFFIRMED PHARMA, LLC——
2177PARTILLION BIOSCIENCE CORPORATION——
2178AVADIM HEALTH, INC.—$81M
2179ID4PHARMA, LLC——
2180ENABLE LIFE SCIENCES LLC——
2181General Counsel AI, Inc.—$63M
2182GIWOTECH INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 3
  • P62-ZZ Chemical Inhibitorapplication
  • P62-ZZ Chemical Inhibitorgranted
  • P62-ZZ Chemical Inhibitorapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.